VEXAS syndrome

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Kinase inhibitor 2 substances
Phase II: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

2 trials
  • Sobi Inc. Commercial
    PACRITINIB
    2024-516347-41-00 4 countries 2025 n=36 Orphan
    Recruiting
  • Groupe Francophone Des Myelodysplasies Academic
    MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
    2024-519779-24-00 1 country 2025 n=57
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sobi Inc. Commercial 1 Phase II 1
Groupe Francophone Des Myelodysplasies Academic 1 Phase II 1
New trials by year
2025
2
← All indication landscapes